SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Creemers GJ, Lund B, Verweji J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994; 20: 7396.
  • 2
    Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilised topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 507782.
  • 3
    Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994; 86: 83642.
  • 4
    Rougier P, Bugat E, Douillard J, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 25160.
  • 5
    Rothenberg ML, Eckaedt JR, Kuhne JG, Burris HA, Nelson J, Hilsenbeck SG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 112835.
  • 6
    Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW, Punt CJA, Alexopoulos CG, Dirix L, et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil. Eur J Cancer 1999; 35(1): 549.
  • 7
    Scheithauer V, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 75255.
  • 8
    Rougier P, van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 140718.
  • 9
    Cunningham D, Pyrhonen S, James RD, Punt CJA, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 14138.
  • 10
    Lévi F. Chronopharmacology of anticancer agents. In: RedfernPH, LemmerB, editors. Handbook of experimental pharmacology: physiology and pharmacology of biological rhythms. Chapter 11: cancer chemotherapy. Berlin: Springer-Verlag, 1997: 299331.
  • 11
    Lévi F. Cancer chronotherapy. J Pharm Pharmacol 1999; 51: 8918.
  • 12
    Lévi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed-infusion-rate of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 160817.
  • 13
    Lévi F, Zidani R, Misset JL, for the International Organization for Cancer Chronotherapy. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 6816.
  • 14
    Burns ER, Beland SS. Effect of biological time on the determination of the LD50 of 5-fluorouracil in mice. Pharmacology 1984; 28: 296300.
  • 15
    Smaaland R, Laerum OD, Lote K, Sletvold O, Sothern RB, Bjerknes R. DNA synthesis in human bone marrow is circadian stage dependent. Blood 1991; 77: 260311.
  • 16
    Harris B, Song R, Soong S, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197201.
  • 17
    Lévi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, et al., for the International Organization for Cancer Chronotherapy. A multicenter evaluation of intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil and leucovorin as initial treatment of patients with metastatic colorectal cancer. Cancer 1999;85: 253240.
  • 18
    Garufi C, Lévi F, Aschelter AM, Pace R, Giunta S, Nistico C, et al. A Phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer. Eur J Cancer 1997; 33: 156671.
  • 19
    Garufi C, Aschelter AM, Zappalá A, D'Attino RM, Antonini CGC, Rosati N, et al. Chronomodulated (chrono) infusion of 5-fluorouracil (5-FU) and l-folinic acid (FA) in 91 patients (pts) with metastatic colorectal cancer: the Regina Elena Cancer Institute experience. Eur J Cancer 1999; 35: 221.
  • 20
    Curé H, Adenis A, Tubiana-Mathieu N, Ouabdesselam R, Kwiatkowski F, Perpoint B, et al. Phase II trial of chronomodulated (cm) high dose 5-fluorouracil (5-FU) and l-folinic acid (l-fa) in patients with metastatic colorectal cancer (MCC). Proc Am Soc Clin Oncol 1998; 17: 1048.
  • 21
    Aaronson BK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The EORTC QLQ-30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 36576.
  • 22
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 20715.
  • 23
    Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, et al. Irinotecan (CPT-11) high dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86: 4459.
  • 24
    Lévi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, et al. A chronopharmacologic Phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992;69: 893900.
  • 25
    Garufi C, Brienza S, Misset JL, et al. Addition of oxaliplatin to chronomodulated 5-fluorouracil and folinic acid for reversal of acquired chemoresistance in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1995; 14: 192.
  • 26
    Ducreux M, Ychou M, Seitz JF, Bonnay M, Bexon A, Armand JP, et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999; 17: 29018.
  • 27
    Vanhoefer U, Harstrick A, Köhne CH, Achterrath W, Rustum YM, Seeber S, et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 1999; 17: 90713.
  • 28
    Falcone A, Danesi R, Allegrini G, Masi G, Di Paolo A, Lencioni M, et al. Escalating dose irinotecan (CPT-11) immediately prior or after 5-fluorouracil (5-FU) 48 hours infusion + leucovorin (LV): pharmacokinetic and pharmacodynamic interactions in chemotherapy-naive metastatic colorectal cancer patients. Proc Am Soc Clin Oncol 1999; 18: 924.
  • 29
    Guichard S, Hennebelle I, Bugat R, Canal P. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 1998; 55: 66776.
  • 30
    Abiegerges D, Chabot GG, Armand JP, Herait P, Gouyette A, Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every three weeks in cancer patients. J Clin Oncol 1995; 13: 20121.
  • 31
    Köhne CH, Schöffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998; 16: 41826.
  • 32
    Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 10417.
  • 33
    Bertheault-Cvitkovic F, Jami A, Ithzaki M, Deprés Brummer P, Brienza S, Adam R, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 29508.
  • 34
    Ohdo S, Makinosumi T, Ishizaki T, Yukawa E, Higuchi S, Nakano S, et al. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J Pharmacol Exp Ther 1997; 283: 13838.
  • 35
    Filipski E, Lévi F, Vadrot N, Li XM, Mormont C, Lemaigre G, et al. Circadian changes in irinotecan toxicity in mice. Proc AACR 1997; 38: 2048.
  • 36
    D'Attino RM, Filipski E, Granda TG, Garufi C, Terzoli E, Lévi F. Irinotecan (CPT-11) and oxaliplatin (l-OHP) synergistic activity at specific circadian times in tumor-bearing mice. Proc AACR 2000; 41: 1268.